KA2507 monohydrochloride

KA2507 monohydrochloride Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Shanghai SuperLan Chemcial Technique Centre  
Tel: 0-2022843681 15618226720
Email: chaolaichem@foxmail.com
Company Name: Jinan Jiuli Biotechnology Co. , Ltd.  
Tel: 15865264761
Email: 486064515@qq.com
Company Name: Beijing Jin Ming Biotechnology Co., Ltd.  
Tel: 010-60605840
Email: psaitong@jm-bio.com

KA2507 monohydrochloride manufacturers

KA2507 monohydrochloride Basic information
Product Name:KA2507 monohydrochloride
Synonyms:KA2507 monohydrochloride;Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy-, hydrochloride (1:1)
CAS:2972712-63-1
MF:C16H14N6O2.ClH
MW:358.78
EINECS:
Product Categories:
Mol File:2972712-63-1.mol
KA2507 monohydrochloride Structure
KA2507 monohydrochloride Chemical Properties
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
KA2507 monohydrochloride Usage And Synthesis
UsesKA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects[1].
in vivo

KA2507 hydrochloride (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model[1].
KA2507 hydrochloride also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models[1].
Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 hydrochloride administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I[1].
KA2507 hydrochloride exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg)[1].

Animal Model:Male C57BL/6 mice, B16-F10 melanoma model[1]
Dosage:100 mg/kg, 200 mg/kg,
Administration:P.o.; once a day for 20 days
Result:Inhibited tumor growth in the syngeneic B16-F10 mouse melanoma model.
Animal Model:Male C57BL/6 mice, B16-F10 melanoma model[1]
Dosage:200 mg/kg (Pharmacokinetic Analysis)
Administration:Oral administration
Result:Oral bioavailability (15%), Cmax (300 ng/mL).
References[1] Tsimberidou AM, et al. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021;27(13):3584-3594. DOI:10.1158/1078-0432.CCR-21-0238
KA2507 monohydrochloride Preparation Products And Raw materials
Tag:KA2507 monohydrochloride(2972712-63-1) Related Product Information
[4-[(Hydroxyamino)carbonyl]phenyl]carbamic acid [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide Tucidinostat (Chidamide) LMK-235 4-Phenylbutyric acid Entinostat